Taking these results together with our previous findings that TQHXD exerted therapeutic action by activating CD36 and CX3CR1 on macrophage surfaces in mice with TBI‐induced intestinal inflammation and IMB mucosal barrier damage, we inferred that TQHXD's mechanism of action was stimulation of CD36/NR4A1/15‐LO signaling in mice with TBI‐induced intestinal inflammation and IMB mucosal barrier damage by regulating the IMB's mucosal biological, chemical, epithelial, and immune barriers. This evidence concerns the gene CD36 and gastroenteritis.